去纤苷用法以及用量

/Defitelio has received marketing authorization from the European Commission for the treatment of severe hepatic VOD in hematopoietic stem cell transplantation (HSCT). A phase 3 randomized controlled trial of defibrination to prevent hepatic VOD in pediatric transplant patients has also been completed. Defitelio/Defitelio has been generally well tolerated; the most common adverse reactions observed during premarketing use to treat hepatic VOD were bleeding, hypotension, and coagulopathy.

Defitelio usage and dosage: 1. Recommended dose: The recommended dose of Defitelio/Defitelio for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Administer Defitelio for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue Defitelio until resolution of VOD or up to a maximum of 60 days. 2. Dosing Instructions: Defitelio must be diluted before infusion; before administration of Defitelio, confirm that the patient has not experienced clinically significant bleeding and is hemodynamically stable to no more than 1 vasopressin, constant over a 2-hour period. Administer Defitelio by intravenous infusion; use an infusion set equipped with a 0.2 micron in-line filter to administer a diluted Defitelio solution. Use 5% Glucose Injection, USP or 0.9% Sodium Chloride Injection, USP immediately before and after administration. Flush the intravenous administration line (peripheral or central). /Defitelio should not be coadministered with other intravenous medications at the same time and in the same intravenous line.